Viamet Data for VT-1161 and VT-1598 to be Presented at The American Society for Microbiology’s ASM Microbe 2017 Conference

Presentations to include results of the highly successful Phase 2b study of VT-1161 in the treatment of recurrent vulvovaginal candidiasis (RVVC) and highlight the potent activity of Viamet’s product candidates against a breadth of endemic and multi-drug resistant fungal species

Viamet Pharmaceuticals, Inc. today announced that data from its VT-1161 and VT-1598 therapeutic programs will be presented in multiple posters at The American Society for Microbiology’s ASM Microbe 2017 Conference, being held June 1-5 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The posters will include the first public presentation of Viamet’s successful Phase 2b results for VT-1161 in the treatment of recurrent vulvovaginal candidiasis (RVVC), and highlight the potent activity of Viamet’s antifungal candidates against a breadth of endemic and multi-drug resistant fungal species.